Abstract
Recent studies have shown efficacy to slow the decrease of forced vital capacity in patients with idiopathic pulmonary fibrosis. This summary refers to recent anti-fibrotic medications and describes current studies, indication for treatment and side effects, as well as discusses open questions of treatment.
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Evidence-Based Medicine
-
Fibrinolytic Agents / administration & dosage*
-
Fibrinolytic Agents / adverse effects
-
Humans
-
Idiopathic Pulmonary Fibrosis / diagnosis*
-
Idiopathic Pulmonary Fibrosis / drug therapy*
-
Indoles / administration & dosage*
-
Indoles / adverse effects
-
Kidney Diseases / chemically induced
-
Kidney Diseases / prevention & control*
-
Pyridones / administration & dosage*
-
Pyridones / adverse effects
-
Respiratory System Agents / administration & dosage
-
Respiratory System Agents / adverse effects
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Fibrinolytic Agents
-
Indoles
-
Pyridones
-
Respiratory System Agents
-
pirfenidone
-
nintedanib